AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03892564
Drug: Control, irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Trial: NCT01037985
Drug: EXC 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intradermal injections of EXC 001 and placebo
Trial: NCT01037985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intradermal injections of EXC 001 and placebo
Trial: NCT01401023
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: : Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
Trial: NCT03196973
Drug: DF289 plus DF277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vial into the affected ear twice daily for 7 days
Trial: NCT02039089
Drug: E2006 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02039089
Drug: E2006 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02039089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00408772
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00112840
Drug: CCI-779
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
Trial: NCT01641341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule will not contain active treatment ingredients.
Trial: NCT01018615
Drug: silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, 700 mg, twice daily, 12 days
Trial: NCT00490802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00973115
Drug: Simvastatin CR
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01381809
Drug: Group 2: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
Trial: NCT01381809
Drug: Group 1: Epoetin alfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
Trial: NCT00803387
Drug: Travaprost without BAC (Travatan Z)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
Trial: NCT00674479
Drug: INCB018424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
Trial: NCT00105313
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01440829
Drug: L-ornithine-L-aspartate
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
Trial: NCT01261494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules,oral administration,4 capsules per day before breakfast
Trial: NCT00369408
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
Trial: NCT02394028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
Trial: NCT04433078
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 MG Tablet
Trial: NCT04433078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet
Trial: NCT01519752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied to affected area once a day for 28 days
Trial: NCT00198289
Drug: Aurexis® (tefibazumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02981173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
Trial: NCT04652349
Drug: HGP1910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04652349
Drug: HCP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04652349
Drug: HGP1909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT04652349
Drug: HGP1911
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once daily for 8 weeks orally.
Trial: NCT00193726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day for 5 days prior to each cycle of chemotherapy
Trial: NCT01893879
Drug: placebo for study drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04261439
Drug: NIZ985
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIZ985 injection
Trial: NCT02162550
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly injection
Trial: NCT03381521
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The normal saline was used for injection solution
Trial: NCT02903966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
Trial: NCT03050814
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
Trial: NCT03050814
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
Trial: NCT02612844
Drug: NNC0143-0406
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive one single dose only Subcutanesously (s.c., under the skin)
Trial: NCT02425891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Trial: NCT02133820
Drug: 4 mg 12 hourly capsule - strong pain killer fed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02133820
Drug: 12 hourly capsule strong painkiller with antagonist fasted)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02133820
Drug: 4 mg 12 hourly capsule strong painkiller with antagonist fed
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01991301
Drug: carfilzumib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
Trial: NCT02931214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02548806
Drug: Catapres 100μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catapres tablet 100μg, single dose
Trial: NCT00281554
Drug: RSD1235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01488045
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
Trial: NCT01040689
Drug: Placebo (for Tiotropium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Tiotropium 18 mcg) delivered by HandiHaler
Trial: NCT01043601
Drug: Inhaled PT005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled, twice daily for 1 week duration
Trial: NCT01043601
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled, twice daily for 1 week duration
Trial: NCT02355236
Drug: Naproxen/Esomeprazol 500/20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, b.i.d.
Trial: NCT02355236
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, o.d.
Trial: NCT02943577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Trial: NCT02355236
Drug: Naxozol-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (which is identical to Naxozol), b.i.d.
Trial: NCT02355236
Drug: Comparator-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule (which is identical to Celebrex), o.d.
Trial: NCT03564288
Drug: SKI-G-801
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SKI-G-801 is administered as an IV infusion over 10 minutes
Trial: NCT00127634
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific dose, inhaled, before meals, 24 months, up to 36 months
Trial: NCT04042220
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
Trial: NCT02462811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02827487
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
Trial: NCT02932579
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg
Trial: NCT02827487
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
Trial: NCT02827487
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
Trial: NCT01370772
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: •FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
Trial: NCT03410602
Drug: Subgingival irrigation
RxNorm normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
Trial: NCT04401735
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT02932579
Drug: Oxycontin/acetominophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
Trial: NCT00074711
Drug: Calcium Phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
Trial: NCT00083551
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
Trial: NCT00083551
Drug: Recombinant GM-CSF
RxNorm normalized name: recombinant human GM-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
Trial: NCT02622802
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
Trial: NCT02622802
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
Trial: NCT00881686
Drug: adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5mg/Kg adenosine will be administered intravenously before surgery
Trial: NCT00006241
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00604955
Drug: Paromomycin sulfate
RxNorm normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
Trial: NCT02379715
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01987843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03535558
Drug: Fluoroquinolone (FQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
Trial: NCT03535558
Drug: Azithromycin (AZ)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
Trial: NCT03530189
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
Trial: NCT03530189
Drug: bolus of dextrose, reducing the glucose infusion, insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.
Trial: NCT04918069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo ointment
Trial: NCT04454151
Drug: Azithromycin Tablets
RxNorm normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
Trial: NCT00671190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally once daily for up to 5 days
Trial: NCT02755116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo by mouth prior to anesthetic induction
Trial: NCT00081263
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00783263
Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
Trial: NCT00783263
Drug: Comparator: rosuvastatin 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
Trial: NCT00783263
Drug: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
Trial: NCT00783263
Drug: Comparator: rosuvastatin 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
Trial: NCT00421460
Drug: Testosterone Undecanoate,1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duration for 4 injections
Trial: NCT03606707
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular steroid injection for atlantoaxial joint
Trial: NCT02219724
Drug: MOXR0916
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
Trial: NCT00110864
Drug: PN2034
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01110486
Drug: ABT-348
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Trial: NCT01110486
Drug: ABT-348
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
Trial: NCT01110486
Drug: ABT-348
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
Trial: NCT02265445
Drug: Deescalation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
Trial: NCT00284258
Drug: CPT-11, 5-FU and l-LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
Trial: NCT00998881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04134273
Drug: CLPG Topical Gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
Trial: NCT04134273
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin Phosphate topical gel 1%
Trial: NCT04134273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Trial: NCT02949375
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel capsule to be taken daily for 28 days
Trial: NCT02949375
Drug: Active Comparator:4.5mg GRI-0621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5mg GRI-0621 gel capsule to be taken daily for 28 days
Trial: NCT02949375
Drug: Active Comparator: 6.0mg GRI-0621
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.0mg GRI-0621 gel capsule to be taken daily for 28 days
Trial: NCT00670813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
Trial: NCT00102336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
Trial: NCT00847249
Drug: AZD9164
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.